Please login to the form below

Not currently logged in
Email:
Password:

Pfizer considers Icagen options

Pfizer is considering a "strategic transaction" with Icagen, a US biotechnology company, in which it holds a 14 per cent stake in

Pfizer is considering a "strategic transaction" with Icagen, a US biotechnology company, in which it holds a 14 per cent stake in.

In a regulatory filing, Pfizer said Icagen representatives and Pfizer employees have engaged in preliminary discussions, and that Icagen had provided access to due diligence materials.

Pfizer said the continuing talks could lead to an extension or amendment of their longstanding agreement, including a change in its control "by means of a stock or asset acquisition or merger."

Icagen acknowledged that it is engaged in preliminary discussions with Pfizer, however, said there can be no assurance any agreement will be reached.

In 2007 Pfizer forged a research and licensing deal with Icagen, relating to medicines to treat pain and related disorders.

27th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics